Zurich based CUTISS is developing a personalized tissue therapy that enables on-demand production of living skin for surgeries episode artwork

EPISODE · May 1, 2025 · 14 MIN

Zurich based CUTISS is developing a personalized tissue therapy that enables on-demand production of living skin for surgeries

from BiotechTV - News · host BiotechTV

Co-Founder & CEO Daniela Marino describes why CUTISS believes denovoSKIN is superior to autografting. She describes how they make it, walks us through the company's on-site GMP facility, and she discusses the clinical experience to date. The therapy is already in a phase 3 study in Europe.

Co-Founder & CEO Daniela Marino describes why CUTISS believes denovoSKIN is superior to autografting. She describes how they make it, walks us through the company's on-site GMP facility, and she discusses the clinical experience to date. The therapy is already in a phase 3 study in Europe.

NOW PLAYING

Zurich based CUTISS is developing a personalized tissue therapy that enables on-demand production of living skin for surgeries

0:00 14:57

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 14 minutes long.

When was this BiotechTV - News episode published?

This episode was published on May 1, 2025.

What is this episode about?

Co-Founder & CEO Daniela Marino describes why CUTISS believes denovoSKIN is superior to autografting. She describes how they make it, walks us through the company's on-site GMP facility, and she discusses the clinical experience to date. The therapy...

Can I download this BiotechTV - News episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!